To include your compound in the COVID-19 Resource Center, submit it here.

Gavestinel: Phase III

In GSK's North American Glycine Antagonist in Neuroprotection (GAIN) study of 1,367 patients with

Read the full 143 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE